PIK3CA and breast carcinoma: Those inhibitors specifically bind the phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which mediates the downstream signaling of PI3K. It has shown synergistic antitumor activity with endocrine therapy against HR+ breast cancer in both preclinical and clinical results [9].